Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial.
Grosicki S, Lech-Maranda E, Govind Babu K, Rybka J, Litvinskaya E, Loscertales J, Kriachok I, Kłoczko J, Rekhtman G, Homenda W, Blonski J, Stefanelli T, Vincent G, Banerjee H, Robak T. Grosicki S, et al. Among authors: banerjee h. Leuk Lymphoma. 2020 Jul;61(7):1748-1751. doi: 10.1080/10428194.2020.1732960. Epub 2020 Feb 28. Leuk Lymphoma. 2020. PMID: 32107948 No abstract available.
Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus.
Atkinson V, Robert C, Grob JJ, Gogas H, Dutriaux C, Demidov L, Gupta A, Menzies AM, Ryll B, Miranda F, Banerjee H, Lau M, Del Vecchio M. Atkinson V, et al. Among authors: banerjee h. Eur J Cancer. 2022 Mar;163:79-87. doi: 10.1016/j.ejca.2021.12.015. Epub 2022 Jan 14. Eur J Cancer. 2022. PMID: 35042070 Free article. Clinical Trial.
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III).
Atkinson VG, Quaglino P, Aglietta M, Del Vecchio M, Depenni R, Consoli F, Bafaloukos D, Ferrucci PF, Tulyte S, Krajsová I, Ascierto PA, Gueli R, Arance A, Gogas H, Banerjee H, Saliba T, de Jong E, Neyns B. Atkinson VG, et al. Among authors: banerjee h. Cancers (Basel). 2021 May 18;13(10):2466. doi: 10.3390/cancers13102466. Cancers (Basel). 2021. PMID: 34070224 Free PMC article.
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Vellano CP, et al. Among authors: banerjee h. Nature. 2022 Jun;606(7915):797-803. doi: 10.1038/s41586-022-04833-8. Epub 2022 Jun 15. Nature. 2022. PMID: 35705814 Free PMC article.
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Vellano CP, et al. Among authors: banerjee h. Nature. 2023 Jan;613(7945):E3. doi: 10.1038/s41586-022-05632-x. Nature. 2023. PMID: 36627494 No abstract available.
Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
Wilmott JS, Tawbi H, Engh JA, Amankulor NM, Shivalingam B, Banerjee H, Vergara IA, Lee H, Johansson PA, Ferguson PM, Saiag P, Robert C, Grob JJ, Butterfield LH, Scolyer RA, Kirkwood JM, Long GV, Davies MA. Wilmott JS, et al. Among authors: banerjee h. Clin Cancer Res. 2023 Feb 1;29(3):521-531. doi: 10.1158/1078-0432.CCR-22-2581. Clin Cancer Res. 2023. PMID: 36477181 Free PMC article. Clinical Trial.
140 results